About This Event
Verona Pharma (Nasdaq: VRNA), a biopharmaceutical company focused on respiratory diseases, visits the Nasdaq MarketSite in Times Square, to celebrate the approval of OhtuvayreTM (ensifentrine) in the US for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”). Ohtuvayre is the first novel inhaled product available for the treatment of COPD in more than 20 years.
In honor of the occasion, David Zaccardelli, Pharm. D., President and CEO of Verona Pharma, ring the Closing Bell.
